Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.31 |
| ▸ | TLR2 | O60603 | 2/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485145 | 0.95 | GLP1R (0.50) | GLP1RKDM4EEGLN1KDM2ACTSL | |
| SCHEMBL3485150 | 0.95 | GLP1R (0.50) | GLP1RKDM4EEGLN1KDM2ACTSL | |
| SCHEMBL3485821 | 0.95 | GLP1R (0.50) | GLP1RKDM4EEGLN1KDM2ACTSL | |
| SCHEMBL13498595 | 0.89 | GLP1R (0.41) | GLP1RTTR | |
| SCHEMBL3485672 | 0.82 | GLP1R (0.56) | GLP1RTLR2 | |
| SCHEMBL3485679 | 0.82 | GLP1R (0.56) | GLP1RTLR2 | |
| SCHEMBL16326833 | 0.81 | GLP1R (0.53) | GLP1RTLR2 | |
| SCHEMBL3484885 | 0.80 | GLP1R (0.54) | GLP1RTLR2 | |
| SCHEMBL4517738 | 0.80 | GLP1R (0.54) | GLP1RTLR2 | |
| SCHEMBL18911933 | 0.79 | GLP1R (0.45) | GLP1RCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | GALE, GALNT2, GALNT1 | GLP1R 2352/4885KDM4E 4442/4885EGLN1 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.